Archives
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-29
This study presents an intravesical lipid nanoparticle platform for delivering chemically modified CDKN1A/p21 mRNA directly to bladder tumors. The findings show localized p21 restoration, suppression of tumor growth, and limited systemic distribution in an orthotopic mouse model, while also defining important translational questions for repeated dosing and mRNA manufacturing.
-
Ciprofloxacin: Mechanism, Evidence, and Research Use
2026-08-28
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Its validated research roles include DNA replication inhibition, antimicrobial resistance research, and investigation of ciprofloxacin-loaded nanomedicine platforms.
-
Letrozole: Practical Aromatase Inhibition Workflows
2026-08-28
Letrozole enables controlled studies of estrogen synthesis, ERα regulation, and endocrine feedback across enzyme and cell-based models. This guide translates its reversible mechanism into practical dosing, assay-design, and troubleshooting strategies for reproducible breast cancer research.
-
BCL6–ESM1 Axis Drives HCC Immune Evasion
2026-08-27
Li et al. identify cancer-cell BCL6 as a driver of hepatocellular carcinoma progression that suppresses tumor-infiltrating CD4+ T-cell recruitment and cytotoxicity through ESM1-associated signaling. The study shifts attention beyond CD8+ T cells and provides a mechanistic framework for investigating paracrine immune escape in HCC.
-
Firefly Luciferase mRNA: A Signal-First Guide
2026-08-27
Firefly Luciferase mRNA is more than a luminescent endpoint: it is a tool for separating transcript quality, delivery, translation, and cell-state effects. This guide uses EZ Cap™ chemistry and recent lipid nanoparticle research to build more interpretable mRNA assays.
-
D-Luciferin Potassium Salt for BLI Workflows
2026-08-26
D-Luciferin potassium salt supports reproducible firefly luciferase readouts across in vivo cell tracking, promoter studies, and ATP-linked assays. This practical guide connects the product to the VwDODA stress-adaptation study while separating validated bioluminescence workflows from exploratory plant-biology applications.
-
PEI MW 40,000 for Stress-Pathway Assays
2026-08-26
Polyethylenimine Linear, PEI MW 40,000 can do more than support routine DNA delivery: it can help construct controlled transient gene expression experiments around mitochondrial stress, translation, and barrier biology. This article connects K1029 workflow design with findings from a recent arsenic-induced blood-testis barrier study while emphasizing assay controls and interpretation.
-
KU-55933 Workflow for ATM Kinase Inhibition
2026-08-25
Build a reproducible KU-55933 workflow around ATM-dependent signaling, phospho-Akt analysis, cell-cycle profiling, and cancer-cell phenotyping. The guide also shows how to use the compound as an exploratory perturbation when studying DNA damage, genome integrity, and the nuclear cGAS–L1 axis.
-
Mouse Neutrophil Cell Isolation in Immunotherapy
2026-08-25
Neutrophils are moving from experimental bystanders to programmable effectors in cancer immunotherapy. This thought-leadership article explains why activation-conscious mouse neutrophil isolation is strategically important for validating neutrophil-targeted nanovaccines and translating mechanistic findings into reproducible assays.
-
4Q Design for Stable Polymeric mRNA Delivery
2026-08-24
Shi and colleagues introduced a “4Q” framework that separates mRNA delivery into vector stability, diffusion, cellular entry, and intracellular release. Their polycatechol PBD system addressed the trade-off between room-temperature storage and cytoplasmic release, producing stable polyplexes and substantially stronger in vivo transfection than a jetPEI/mRNA comparator.
-
Ibrexafungerp: Translational Leverage Against Candida
2026-08-24
Ibrexafungerp, also known as MK 3118, illustrates how a differentiated glucan synthase mechanism can create translational value beyond conventional susceptibility results. This article connects resistance biology, acidic-pH activity, standardized assay design, delayed-treatment animal models, and clinical strategy to help researchers evaluate the compound with greater rigor and clearer development priorities.
-
IGF2BP1–THBS1–TLR4 Axis in Pulmonary Fibrosis
2026-08-23
The 2025 reference study identifies an m6A-dependent IGF2BP1–THBS1–TLR4 pathway that links macrophage RNA regulation to glycolytic reprogramming and fibrotic polarization in pulmonary fibrosis. Its knockdown, rescue, tissue, and metabolic experiments provide a mechanistic framework for interpreting macrophage contributions to fibrosis while highlighting important limits of the bleomycin model.
-
Blebbistatin in Structure–Function Assays
2026-08-22
(±)-Blebbistatin is a reversible non-muscle myosin II inhibitor for dissecting force-dependent changes in cell behavior. This guide connects its mechanism and handling with multimodal structure–function imaging, emphasizing assay interpretation, controls, and cross-domain limitations.
-
Peptidisc-Assisted Nanobody Multimerization
2026-08-22
The reference preprint introduces peptidisc-assisted hydrophobic clustering as a way to assemble nanobodies into soluble multimeric, bispecific, and autofluorescent proteins. Its results indicate that membrane-mimetic stabilization can preserve hydrophobically driven assemblies while improving avidity and expanding nanobody engineering options beyond tandem fusion or scaffold-based designs.
-
Cisplatin (CDDP): Workflows for Resistance Studies
2026-08-21
Turn Cisplatin (CDDP) into a controlled benchmark for DNA damage, apoptosis, ferroptosis, and chemotherapy resistance studies. This practical guide connects cell viability assays with mechanistic validation and carefully framed xenograft applications.